Canada awards SIGA $15M contract for smallpox treatment supply
SIGA Technologies (NASDAQ:SIGA) received a $15M contract from Canada for oral TPOXX, an antiviral for smallpox. The deal runs until 2031, with $9M committed in the first three years. This is the second such contract, following a $14M agreement in 2020. The medication is approved by Health Canada for smallpox treatment.
How this was made
The 30-second read
Why it matters
A new Canadian Department of National Defence Strategic Medical Countermeasures Program contract extends supply through 2031, with about $9M firm commitments over the first three years and about $6M contingent on options.
Market read
The contract is a concrete, multi-year government procurement update that can affect SIGA’s revenue outlook and biodefense sentiment.
What to watch
Traders may discount near-term impact if prior deliveries already covered much of the program and if manufacturing capacity or reimbursement timing constrains revenue recognition.
Background
SIGA’s oral TPOXX (tecovirimat) is a smallpox antiviral approved by Health Canada in November 2021, and Canada has previously awarded TPOXX contracts (April 2020).
Ticker impact
SIGA won a contract worth up to about $15M from Canada’s procurement for oral TPOXX (tecovirimat) supply through March 31, 2031.
Likely upward bias as the market prices in incremental, multi-year government demand and improved contract backlog.
The article discloses a new, named government contract with defined firm and option-backed amounts and a long extension period.
Market effects
Reinforces demand durability for smallpox antiviral suppliers and may support sentiment around biodefense procurement cycles.
Highlights continued Canadian defense medical countermeasure spending, potentially affecting peers with similar government exposure.
Signals ongoing NATO-aligned preparedness procurement, which can influence broader biodefense supply expectations.
Counterpoint
Option exercise portions may not be fully realized, so the upside may be less than the headline “up to” value suggests.
Key entities
- companySIGA Technologies, Inc.
NASDAQ-listed commercial-stage pharmaceutical company supplying oral TPOXX (tecovirimat).
- government_agencyPublic Services and Procurement Canada
Procurement authority awarding the contract on behalf of Canada’s Department of National Defence.
- government_agencyCanadian Department of National Defence
End user for the medication supply under the Strategic Medical Countermeasures Program.
- productOral TPOXX (tecovirimat)
Smallpox antiviral medication covered by the contract.
